Sage Therapeutics Inc (NASDAQ: SAGE) on Monday, plunged -6.08% from the previous trading day, before settling in for the closing price of $12.00. Within the past 52 weeks, SAGE’s price has moved between $9.76 and $58.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 3395.58%. The company achieved an average annual earnings per share of 27.95%. With a float of $49.49 million, this company’s outstanding shares have now reached $60.04 million.
Let’s determine the extent of company efficiency that accounts for 487 employees.
Sage Therapeutics Inc (SAGE) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Sage Therapeutics Inc is 17.76%, while institutional ownership is 91.75%. The most recent insider transaction that took place on Aug 09 ’23, was worth 37,279. In this transaction Director of this company bought 2,000 shares at a rate of $18.64, taking the stock ownership to the 3,000 shares.
Sage Therapeutics Inc (SAGE) Recent Fiscal highlights
As on 3/31/2024, Multinational firm has announced its last quarter scores, in which it reported -2.68 earnings per share (EPS) for the period falling under the consensus outlook (set at -2.55) by -0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.95% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.80% during the next five years compared to -2.28% drop over the previous five years of trading.
Sage Therapeutics Inc (NASDAQ: SAGE) Trading Performance Indicators
Sage Therapeutics Inc (SAGE) is currently performing well based on its current performance indicators. A quick ratio of 12.22 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.40, a number that is poised to hit -1.65 in the next quarter and is forecasted to reach -5.14 in one year’s time.
Technical Analysis of Sage Therapeutics Inc (SAGE)
Looking closely at Sage Therapeutics Inc (NASDAQ: SAGE), its last 5-days average volume was 1.98 million, which is a jump from its year-to-date volume of 1.11 million. As of the previous 9 days, the stock’s Stochastic %D was 82.89%. Additionally, its Average True Range was 0.78.
During the past 100 days, Sage Therapeutics Inc’s (SAGE) raw stochastic average was set at 8.43%, which indicates a significant decrease from 63.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.11% in the past 14 days, which was higher than the 64.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.69, while its 200-day Moving Average is $19.06. However, in the short run, Sage Therapeutics Inc’s stock first resistance to watch stands at $11.86. Second resistance stands at $12.44. The third major resistance level sits at $12.80. If the price goes on to break the first support level at $10.92, it is likely to go to the next support level at $10.56. Now, if the price goes above the second support level, the third support stands at $9.98.
Sage Therapeutics Inc (NASDAQ: SAGE) Key Stats
Market capitalization of the company is 678.23 million based on 60,182K outstanding shares. Right now, sales total 86,460 K and income totals -541,490 K. The company made 7,900 K in profit during its latest quarter, and -108,480 K in sales during its previous quarter.
